148P Phase III study of everolimus or placebo in addition to adjuvant hormone therapy for high risk early breast cancer: Subgroup analysis of the UCBG UNIRAD trial

Paul Cottu ,M.A Mouret Reynier,A-C Hardy-Bessard,Sylvie Giacchetti ,Audrey Mailliez ,Florence Dalenc ,J-L Canon ,Julien Grenier ,J.p Jacquin ,Judith Bliss ,Fabrice André ,Sylvie Chabaud ,Jérôme Lemonnier ,D Cameron ,Philippe Barthélémy ,Laure Kaluzinski ,Eric Legouffe ,Murray Brunt ,Djelila Allouache ,Thomas Bachelot

doi:10.1016/j.annonc.2021.08.429

Abstract

The double blind randomized UNIRAD trial (NCT01805271) showed that adding Everolimus (EVE) to adjuvant endocrine therapy (ET) for high-risk early breast cancer (BC) does not improve 3-year disease-free survival (iDFS) compared with ET alone. We report the subgroup analysis focusing on the pre-specified stratification factors.

Full Text